With positive interim results from a global Phase II study in hand, the management at Hope Medicine (HopeMed), a Chinese biotech specialized in women’s health, is entertaining hopes of a first-line treatment for endometriosis-associated pain.
HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain
Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.
